U.S. Food and Drug Administration (FDA)
FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
On September 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
September 17, 2024